In this video, Dr. Nicholas Kavoussi sits down with Dr. Arthur L. Burnett, II, of the Urology Times Editorial Council to discuss his 2016 AUA presentation, "Preoperative urine cultures for prosthetic urological surgery: What is the evidence?"
"LUTS is an important health care burden, and health care professionals should be screening for its presence in men at risk," writes Steven A. Kaplan, MD.
A new meta-analysis links moderate-to-severe lower urinary tract symptoms (LUTS) to heart disease in men, possibly because unhealthy lifestyles boost the risks of both conditions.
A treatment system that uses steam to ablate prostate tissue (Rezūm, NxThera, Inc.) can be considered as a first-line therapy for the treatment of lower urinary tract symptoms secondary to BPH, say investigators from a non-randomized multicenter pilot study with 2-year duration of successful outcomes.
This article provides an update on the risk factors for stone disease and its presentation in children, and offers practical tips on its evaluation, treatment, and prevention.
A bladder cancer drug-device combination, a localized prostate cancer agent, and a new surgical robot are among other treatments in the pipeline discussed in this round-up.
Other female urology topics discussed at this year's AUA meeting include preoperative urodynamics for women undergoing prolapse surgery and a study on nocturia.
Other products discussed in this roundup include a plasma vaporization device, a laser fiber safety device, and more.
Other basic science research pearls include preliminary evidence from a porcine model suggesting botulinum toxin type A facilitates ureteral stone passage and the identification of two different microdeletions in the NELL1 gene on chromosome 11 in men with Peyronie's disease.
Four-year data on the prostatic urethral lift (UroLift) and data on a new water-jet ablation treatment were among BPH/LUTS highlights from this year’s meeting.